Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX1305 (recombinant human nerve growth factor) in optic nerve damage due to open-angle glaucoma
CTR20230957Phase 2Active
- Sponsor
- Jiangsu Zhongxin Pharmaceutical
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SMR001 in Glaucoma, sponsored by Jiangsu Zhongxin Pharmaceutical. Started May 2023; status: active.
02
Drugs
SMR001
03
Conditions
Glaucoma
Beyond the preview
Go deeper on CTR20230957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230957.